Pioglitazone is a drug used in the management of type 2 diabetes mellitus. Pioglitazone is the third marketed thiazolidinedione group of oral antidiabetics, the first is troglitazone which is no longer available due to hepatotoxicity, and the second is rosiglitazone, still on the market. This activity reviews the indications, mechanism of action, and contraindications for pioglitazone in managing type 2 diabetes mellitus. This activity highlights the mechanism of action, adverse effect profile, monitoring, and relevant interactions.

**Objectives:**
- Identify the mechanism of action of pioglitazone.
- Describe the potential adverse effects of pioglitazone.
- Review dosing of pioglitazone.
- Summarize interprofessional team strategies to improve care coordination and communication to use pioglitazone in diabetes mellitus management and improve outcomes while minimizing adverse effects.